Recently published results of a phase II clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy, which is the standard of care.
A study has found that neonatal concentrations of eight detectable inflammatory markers were significantly different in children later diagnosed with B-cell precursor acute lymphoblastic leukemia compared with controls.
A University of Houston researcher has developed a synthetic compound, MA242, that can inhibit two of the major pathways of highly aggressive pancreatic cancer.
The National Comprehensive Cancer Network announced a collaboration with Eli Lilly and Co. to offer a new opportunity seeking proposals to bridge gaps in care for gastric and gastroesophageal junction cancer patients in the U.S. The Request for Proposals outlines the scope and process that will be followed for the submission of Letters of Intent.
Nearly 350 organizations took part in the sixth annual Rally for Medical Research Hill Day—led by the American Association for Cancer Research—on Sept. 12 and 13 to advocate for sustained annual funding increases for NIH.
Stand Up To Cancer said more than $123.6 million has been pledged collectively so far in connection with the Sept. 7 “roadblock” fundraising telecast in the United States and Canada.
C. David AllisMichael GrunsteinJohn B. GlenJoan Argetsinger SteitzThe Albert and Mary Lasker Foundation announced Sept. 11 the winners of its 2018 Lasker Awards:
In a new UCLA-led study, funded by a $3.2 million NCI grant, researchers will examine how perception and cognition interact in the interpretation of breast biopsy images. The aim is to improve physicians' diagnostic skills and accuracy.
With the approval of 64 new research, product development, and prevention grants totaling more than $177 million, the Cancer Prevention & Research Institute of Texas has awarded $2.15 billion of the $3 billion approved by Texas voters in 2007 to fight cancer.
The Sidney Kimmel Cancer Center – Jefferson Health announced a collaboration with Driver, a first-of-its-kind global technology platform that connects cancer patients to the best treatments, which has launched in the United States and China.
